InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,633.91
(
1.02%
)
US TECH 100
20,107.19
(
0.99%
)
Dow Jones
39,721.36
(
1.09%
)
Brent Oil
85.24
(
0.22%
)
Bitcoin
57,601.33
(
-0.27%
)
Post# of 252557
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 831
Posts 120016
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: genisi post# 151549

Wednesday, 07/27/2016 9:04:08 AM

Wednesday, July 27, 2016 9:04:08 AM

Post# of 252557
TauRx phase-3 trial in AD misses primary endpoints:

http://finance.yahoo.com/news/taurx-reports-first-phase-3-120000719.html

While the TRx-237-015 study in 891 subjects failed to meet its co-primary endpoints, clinically meaningful and statistically significant reductions in the rate of disease progression were observed across three key measures in patients who were treated with LMTX as their only Alzheimer's disease medication.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up